Like most biopharmaceuticals, Regeneron Pharmaceuticals Inc REGN has had a tough 2016. Since the year started, the stock has lost about 31.5 percent of its value. Moreover, in the past five trading sessions, shares tumbled more than 7 percent.
Following the most recent decline, the Vetr crowd seems to believe some extra room for upside has been unlocked, as evidenced by its average price target of $429.65, which implies a potential return of roughly 15.5 percent from current valuations.
Related Link: Here's How Crowdsourced Ratings Can Beat The Market
Seeking to better reflect this upside potential, the Vetr community decided upgrade its rating on shares of Regeneron on Friday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.
Finally, it should be noted that, in accordance with the rating, 93 percent of the crowd’s ratings are bullish.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
